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Abstract
 
Heme oxygenase 1 (HO-1) inhibits apoptosis by regulating cellular prooxidant iron. We now
show that there is an additional mechanism by which HO-1 inhibits apoptosis, namely by gen-
erating the gaseous molecule carbon monoxide (CO). Overexpression of HO-1, or induction
of HO-1 expression by heme, protects endothelial cells (ECs) from apoptosis. When HO-1 en-
zymatic activity is blocked by tin protoporphyrin (SnPPIX) or the action of CO is inhibited by
hemoglobin (Hb), HO-1 no longer prevents EC apoptosis while these reagents do not affect
the antiapoptotic action of bcl-2. Exposure of ECs to exogenous CO, under inhibition of HO-1
activity by SnPPIX, substitutes HO-1 in preventing EC apoptosis. The mechanism of action of
HO-1/CO is dependent on the activation of the p38 mitogen-activated protein kinase
(MAPK) signaling transduction pathway. Expression of HO-1 or exposure of ECs to exoge-
nous CO enhanced p38 MAPK activation by TNF-
 
a
 
. Specific inhibition of p38 MAPK acti-
vation by the pyridinyl imidazol SB203580 or through overexpression of a p38 MAPK domi-
nant negative mutant abrogated the antiapoptotic effect of HO-1. Taken together, these data
demonstrate that the antiapoptotic effect of HO-1 in ECs is mediated by CO and more specif-
ically via the activation of p38 MAPK by CO.
Key words: apoptosis • endothelial cells • heme oxygenase 1 • carbon monoxide • p38 
mitogen-activated protein kinase
 
Introduction
 
In their normally quiescent state, endothelial cells (ECs)
 
1
 
maintain blood flow, allowing the continuous traffic of
plasma and cellular constituents between blood and paren-
chymal tissues. To accomplish this function, ECs must pro-
mote a certain level of vasorelaxation and inhibit leukocyte
adhesion as well as coagulation and thrombosis (for a re-
view, see reference 1). However, when ECs are exposed to
proinflammatory stimuli, they become “activated” and
promote vasoconstriction, leukocyte adhesion, and activa-
tion, as well as coagulation and thrombosis (for reviews, see
references 1–3). These functional changes are due to the
expression by activated ECs of a series of proinflammatory
genes encoding adhesion molecules, cytokines/chemo-
kines, and costimulatory and procoagulant molecules (for
reviews, see references 1–4). To prevent unfettered EC ac-
tivation that could lead to EC injury and apoptosis, the ex-
pression of these proinflammatory genes must be tightly
regulated (5). One of the mechanisms by which this occurs
relies on the expression by activated ECs of “protective
genes” (6–10). One such gene is the stress responsive gene
heme oxygenase 1 (HO-1).
Heme oxygenases are the rate-limiting enzymes in the
catabolism of heme into biliverdin, free iron, and carbon
monoxide (CO), with biliverdin being subsequently catabo-
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aortic endothelial cell; CoPPIX, cobalt protoporphyrin; DFO, deferox-
amine mesylate; EC, endothelial cell; ERK, extracellular signal–regulated
kinase; FePP, iron protoporphyrin; GFP, green fluorescent protein; Hb,
hemoglobin; HO-1, heme oxygenase 1; JNK, c-Jun NH
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-terminal ki-
nase; MAPK, mitogen-activated protein kinase; M
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, monocyte/mac-
 
rophage(s);
 
 
 
ppm, parts per million; SnPPIX, tin protoporphyrin; VASP,
vasodilatator-stimulated phosphoprotein. 
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lyzed into bilirubin (for reviews, see references 11–13). Sev-
eral proinflammatory stimuli that lead to EC activation also
upregulate the expression of HO-1 (for reviews, see refer-
ences 12 and 13). That HO-1 acts as a cytoprotective gene
is suggested by the observation that expression of HO-1 in
vitro prevents EC injury mediated by activated polymor-
phonuclear cells (14), hydrogen peroxide (14, 15), or heme
(15–17).
 
 
 
In addition, expression of HO-1 in vivo suppresses
a variety of inflammatory responses, including endotoxic
shock (17–19), hyperoxia (20), acute pleurisy (21), ischemia
reperfusion injury (22), and graft rejection (23, 24), further
supporting the cytoprotective role of this gene.
We have shown previously that expression of HO-1
prevents ECs from undergoing apoptosis (23). This may be
an important mechanism by which HO-1 exerts its cyto-
protective function, since EC apoptosis, such as it occurs
during acute (25) and chronic inflammation (26), is highly
deleterious. We now demonstrate that the antiapoptotic ef-
fect of HO-1 is mediated through the ability of HO-1 to
generate the gaseous molecule CO. In addition, we dem-
onstrate that CO suppresses EC apoptosis through a mech-
anism that is dependent on the activation of the p38 mito-
gen-activated protein kinase (MAPK) signal transduction
pathway.
 
Materials and Methods
 
Cell Culture.
 
The murine 2F-2B EC line (American Type
Culture Collection) and primary bovine aortic ECs (BAECs)
were cultured as described previously (23, 27).
 
Expression Plasmids.
 
The
 
 
 
b
 
-galactosidase was cloned into the
pcDNA3 vector (Invitrogen) as described previously (28). Two
vectors encoding rat HO-1 cDNA were used. The original vec-
tor encoding the full-length rat HO-1 cDNA under the control
of a the 
 
b
 
-actin enhancer/promoter (
 
b
 
-actin/HO-1) has been
described elsewhere (29). A 1.0-kbp XhoI-HindIII fragment en-
coding the full-length rat HO-1 cDNA was cut from the prHO-1
vector (30) and subcloned into the pcDNA3 vector to achieve
expression of the HO-1 cDNA under the control of the CMV
enhancer/promoter (pcDNA3/HO-1). The mouse Bcl-2 cDNA
was cloned in the pac vector, as described elsewhere (10). p38/
CSBP1 MAPK was amplified from HeLa cDNA by PCR and
cloned into the pcDNA3/HA vector derived from pcDNA3 (In-
vitrogen) by inserting a DNA fragment coding for an epitope de-
rived from the hemagglutinin protein of the human influenza vi-
rus hemagglutinin (HA; MYPYDVPDYASL). A dominant
negative mutant of p38/CSBP1, harboring a T180A and a Y182F
substitution, was generated by overlap extension mutagenesis.
Green fluorescent protein (GFP) cDNA (CLONTECH Labora-
tories, Inc.) was cloned into the pcDNA3-expressing vector.
 
Transient Transfections.
 
BAECs and 2F-2B ECs were tran-
siently transfected as described elsewhere (23, 28). All experi-
ments were carried out 24–48 h after transfection. 
 
b
 
-Galactosi-
dase–transfected cells were detected as described elsewhere (23,
28). The percentage of viable cells was assessed by evaluating the
number of 
 
b
 
-galactosidase–expressing cells that retained normal
morphology, as described elsewhere (23, 28). The number of ran-
dom fields counted was determined to have a minimum of 200
viable transfected cells per control well. The percentage of viable
cells was normalized for each DNA preparation to the number of
Figure 1. HO-1 suppresses EC apoptosis. (A) 2F-2B ECs were trans-
fected with a GFP-expressing plasmid and monitored for GFP expression
by flow cytometry. The percentage of transfected ECs was assessed by
measuring fluorescence intensity in ECs transfected with control
(pcDNA3; filled histogram) versus GFP (open histogram) expression plas-
mids. (B) ECs were cotransfected with b-galactosidase plus control
(pcDNA3) or HO-1 (b-actin/HO-1) expression vectors. EC apoptosis
was induced by TNF-a plus Act.D and apoptosis of b-galactosidase–
transfected ECs was quantified. Gray bars represent ECs treated with
Act.D and black bars represent ECs treated with TNF-a plus Act.D. Re-
sults shown are the mean 6 SD from duplicate wells taken from 1 repre-
sentative experiment out of 10. (C) HO-1 expression was detected in
BAECs by Western blot. No Tr, nontransfected. NT, nontreated. (D)
2F-2B ECs were cotransfected with b-galactosidase plus control
(pcDNA3) or HO-1 (b-actin/HO-1) expression vectors. Gray bars rep-
resent untreated ECs and black bars represent ECs treated with etoposide
(200 mM, 8 h) or subjected to serum deprivation (0.1% FCS for 24 h).
Results shown are the mean 6 SD from duplicate wells taken from one
representative experiment out of three independent experiments. Similar
results were obtained using BAECs. 
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image scanner (Arcus II; Agfa) equipped with FotoLook and
Photoshop
 
®
 
 software. The amount of phosphorylated ERK,
JNK, and p38 MAPK was quantified using ImageQuant
 
®
 
 soft-
ware (Molecular Dynamics). When indicated, membranes were
stripped (62.5 mM Tris-HCl, pH 6.8, 2% SDS, and 100 mM
 
b
 
-mercaptoethanol, 30 min, 50
 
8
 
C). Phosphorylated ERK, JNK,
and p38 MAPK were normalized to the total amount of total
ERK, JNK, and p38 MAPK detected in the same membrane.
 
Flow Cytometry.
 
2F-2B ECs were transfected with the GFP
expression plasmid and harvested 24 h after transfection by
trypsin digestion (0.05% in PBS). ECs were washed in PBS, pH
7.2, 5% FCS, and fluorescent labeling was evaluated using a
FACSort™ equipped with CELLQuest™ software (Becton
Dickinson).
 
Cell Treatment and Reagents.
 
Actinomycin D (Act.D; Sigma-
Aldrich) was dissolved in PBS and added to the culture medium
24 h after transfection.
 
 
 
The Act.D concentration
 
 
 
used corre-
sponded to the optimal concentration necessary to sensitize ECs
to TNF-
 
a
 
–mediated apoptosis, e.g., 10 
 
m
 
g/ml for 2F-2B ECs
and 0.1 
 
m
 
g/ml for BAECs. When indicated, EC apoptosis was
induced by etoposide (200 
 
m
 
M, 8 h; Calbiochem-Novabiochem)
or by serum deprivation (0.1% FCS for 24 h). The iron chelator
deferoxamine mesylate (DFO; Sigma-Aldrich) was dissolved ex-
temporarily in water and added to culture medium (1–100 
 
m
 
M)
1 h before the induction of apoptosis. Hemoglobin (Hb; Sigma-
Aldrich) was dissolved (1 mM) extemporarily in PBS, 10 mM
Na
 
2
 
S
 
2
 
O
 
4
 
, dialyzed against PBS (2 h, 4
 
8
 
C, 1:800 dilution),
 
 
 
and
added to the culture medium (1–100 
 
m
 
M) 6 h after transfection.
The guanylcyclase inhibitor 1H(1,2,4)oxadiazolo(4,3-
 
a
 
)quin-
oxalin-1 (ODQ; Calbiochem-Novabiochem) was dissolved in
DMSO (Sigma-Aldrich) and added to the culture medium (10–
100 
 
m
 
M) 6 h after transfection. Iron protoporphyrin ([FePP]/
Figure 2. The antiapoptotic effect of HO-1 is
dose dependent.  (A)  2F-2B ECs were cotrans-
fected with increasing doses of HO-1 expression
vector (b-actin/HO-1). EC apoptosis was in-
duced by TNF-a plus Act.D. Results shown are
the mean 6 SD from duplicate wells taken from
one representative experiment out of three. Simi-
lar results were obtained using BAECs. (B) The
expression of HO-1 was detected in BAECs by
Western blot. Values indicate the amount of
HO-1 vector (pcDNA3/HO-1) used in each
transfection (ng of DNA per 3 3 105 cells). No
Tr., nontransfected.
Figure 3. The antiapoptotic effect of
HO-1 is dependent on HO enzymatic ac-
tivity. (A) 2F-2B ECs were cotransfected
with b-galactosidase plus pcDNA3, HO-1
(b-actin/HO-1), or bcl-2 expression vec-
tors. Cells were either left untreated (Con-
trol) or treated with the inhibitor of HO
enzymatic activity SnPPIX. CoPPIX, a pro-
toporphyrin that does not inhibit HO enzy-
matic activity, was used as a control treat-
ment. Gray bars represent ECs treated with
Act.D and black bars represent ECs treated
with TNF-a plus Act.D. Results shown are
the mean 6 SD from duplicate wells taken
from one representative experiment out of
three. (B) 2F-2B ECs were transfected with
b-galactosidase plus pcDNA3 expression vectors. ECs were either left untreated (Control) or were treated with SnPPIX and CoPPIX as in A. The results
shown are the mean 6 SD from duplicate wells taken from one representative experiment out of three.
 
transfected cells counted in the absence of the apoptosis-inducing
agent (100% viability). All experiments were performed at least
three times in duplicate.
 
Adenovirus.
 
The recombinant HO-1 adenovirus has been de-
scribed previously (31). The recombinant 
 
b
 
-galactosidase ade-
novirus was a gift of Dr. Robert Gerard (University of Texas
Southwestern Medical Center, Dallas, Texas). Adenoviruses were
produced, extracted, purified, and titrated, as described previ-
ously (28). Confluent BAECs were infected with a multiplicity of
infection of 200 PFU/cell, as described elsewhere (28).
 
Cell Extracts and Western Blot Analysis.
 
Cell extracts were
prepared, electrophoresed under denaturing conditions (10–
12.5% polyacrylamide gels), and transferred into polyvinyldifluo-
ridine membranes (Immobilon P; Millipore), as described else-
where (28). HO-1 was detected using a rabbit anti–human HO-1
polyclonal antibody (StressGen Biotechnologies). Vasodilatator-
stimulated phosphoprotein (VASP) was detected using a rabbit
anti–human VASP polyclonal antibody (Calbiochem-Novabio-
chem). Total and activated/phosphorylated forms of extracellular
signal–regulated kinases (ERK-1 and -2), c-Jun NH
 
2
 
-terminal ki-
nases (JNK-1, -2, and -3), and p38 MAPK were detected using
rabbit polyclonal antibodies directed against the total or phos-
phorylated forms of these MAPKs, according to the manufac-
turer’s suggestions (New England Biolabs, Inc.). 
 
b
 
-Tubulin was
detected using anti–human 
 
b
 
-tubulin monoclonal antibody
(Boehringer).
 
 
 
Primary antibodies were detected using horseradish
peroxidase–conjugated donkey anti–rabbit or goat anti–mouse
IgG secondary antibodies (Pierce Chemical Co.). Peroxidase was
visualized using the enhanced chemiluminescence assay (Amer-
sham Pharmacia Biotech) according to the manufacturer’s in-
structions, and stored in the form of photoradiographs (Biomax™
MS; Eastman Kodak Co.). Digital images were obtained using an 
1018
 
Carbon Monoxide Suppresses Endothelial Cell Apoptosis
Figure 4. Scavenging of CO by Hb sup-
presses the antiapoptotic effect of HO-1.
2F-2B ECs were cotransfected with
b-galactosidase plus control (pcDNA3),
HO-1 (b-actin/HO-1), or bcl-2 expres-
sion vectors. ECs were either left untreated
(0) or were treated with increasing concen-
trations of Hb. Gray bars represent ECs
treated with Act.D and black bars represent
ECs treated with TNF-a plus Act.D. The
results shown are the mean 6 SD from du-
plicate wells taken from one representative
experiment out of four.
Figure 5. Exogenous CO suppresses EC apoptosis in the absence of
HO-1. (A) 2F-2B ECs were transfected with a b-galactosidase expression
vector and exposed to exogenous CO. Gray bars represent ECs treated
with Act.D alone and black bars represent ECs treated with TNF-a plus
Act.D. (B) 2F-2B ECs were transfected with a b-galactosidase expression
vector and exposed to exogenous CO (10,000 ppm) with or without Hb.
Gray bars represent ECs treated with Act.D and black bars represent ECs
treated with TNF-a plus Act.D. (C) 2F-2B ECs were cotransfected with
b-galactosidase and HO-1 (b-actin/HO-1) expression vectors. Where
indicated (1), HO-1 enzymatic activity was inhibited by SnPPIX and/or
exposed to exogenous CO. Gray bars represent ECs treated with Act.D
and black bars represent ECs treated with TNF-a plus Act.D. Results
shown (A, B, and C) are the mean 6 SD from duplicate wells taken from
one representative experiment out of three.
 
heme), cobalt protoporphyrin (CoPPIX),
 
 
 
and tin
 
 
 
protoporphyrin
(SnPPIX; all from Porphyrin Products, Inc.) were dissolved (10
mM) in 100 mM NaOH and conserved at 
 
2
 
20
 
8
 
C until use.
Metalloporphyrins were added to the culture medium (50 
 
m
 
M)
6 h after transfection. The cGMP analogue 8-bromo-cGMP so-
dium salt (8-Br-cGMP; Sigma-Aldrich) was dissolved in water
and added to the culture medium (10–100 
 
m
 
M) 30 min before
the induction of apoptosis. Human recombinant TNF-
 
a
 
 (R&D
Systems) was dissolved in PBS and 1% BSA, and added to the cul-
ture medium (10–100 ng/ml) 24 h after transfection. The p38
MAPK inhibitor pyridinyl imidazol SB203580 (32) was dissolved
in DMSO and added to the culture medium (5–20 
 
m
 
M) 6 h after
transfection.
 
CO Exposure.
 
Cells were exposed to compressed air or vary-
ing concentration of CO (250 and 10,000 parts per million
[ppm]), as described elsewhere (33).
 
Results
 
HO-1 Protects ECs from Apoptosis.
 
TNF-
 
a
 
 induces ap-
optosis of cultured ECs when transcriptional activity is in-
hibited by Act.D (28). We have used this experimental sys-
tem to ask whether transient overexpression of HO-1
could prevent ECs from undergoing apoptosis. We first
evaluated the ability of ECs to be transiently transfected.
To do so, ECs were transfected with a GFP-expressing
plasmid and the percentage of GFP-expressing ECs was
evaluated by flow cytometry. As illustrated in Fig. 1, 45–
50% of ECs expressed the GFP protein 24 h after transfec-
tion. We then tested whether transfection of HO-1 would
prevent ECs from undergoing TNF-
 
a
 
–mediated apoptosis.
To do so, ECs were cotransfected with HO-1 and 
 
b
 
-galac-
tosidase and apoptosis was evaluated by counting the num-
ber of viable 
 
b
 
-galactosidase–expressing ECs. TNF-a plus
Act.D induced apoptosis of control ECs transfected with
the pcDNA3 (60–70% apoptotic ECs). Overexpression of
HO-1 prevented EC apoptosis (5–10% apoptotic ECs; Fig.
1). The expression of HO-1 was confirmed by Western
blot (Fig. 1). Overexpression of HO-1 also prevented EC
apoptosis induced by other proapoptotic stimuli such as
etoposide or serum deprivation, which is in keeping with
similar observations in 293 cells (34). The antiapoptotic ef-
fect of HO-1 was dose dependent in that increasing levels
of HO-1 expression resulted in increased protection from
TNF-a plus Act.D–mediated apoptosis (Fig. 2). The maxi-
mal antiapoptotic effect of HO-1 (90–100% protection)
was reached using 500–1,000 ng of the b-actin/HO-1 ex-1019 Brouard et al.
4). The ability of Hb to block the antiapoptotic effect of
HO-1 was dose dependent, in that increasing concentra-
tions of Hb (3–50 mM) decreased the ability of HO-1 to
prevent EC apoptosis (Fig. 4). Hb did not impair the anti-
apoptotic effect of bcl-2 (Fig. 4), nor did it sensitize control
ECs (pcDNA3) to apoptosis (Fig. 4).
Exogenous CO Can Substitute for HO-1 in Preventing EC
Apoptosis. If CO mediates the antiapoptotic action of
HO-1, then exogenous CO should prevent EC apoptosis.
The data illustrated in Fig. 5 show that this is the case.
When control ECs (transfected with pcDNA3) were ex-
posed to exogenous CO (10,000 ppm), TNF-a–mediated
apoptosis was suppressed (Fig. 5). Exogenous CO also
suppressed EC apoptosis when HO-1 activity was inhib-
ited by SnPPIX, suggesting that CO can prevent EC ap-
optosis in the absence of other biological functions of
HO-1 (Fig. 5). We then tested whether the level of exog-
enous CO used (10,000 ppm) was comparable to that pro-
duced when HO-1 is expressed in ECs. Given that Hb (50
mM) blocks the protective effect of endogenously pro-
duced CO (Fig. 4), we reasoned that if this was the case
for exogenous CO then the effects of exogenous CO may
mimic those of endogenous CO. The antiapoptotic effect
of exogenous CO was suppressed by Hb (50 mM), sug-
gesting that the concentration of exogenous CO (10,000
ppm) used in these experiments is not supraphysiologic
(Fig. 5).
ECs That Express HO-1 Can Suppress Apoptosis of ECs
That Do Not Express HO-1. Given that CO can act as an
intercellular signaling molecule, we hypothesized that ECs
that express HO-1 may generate sufficient levels of CO to
protect neighboring ECs that do not express HO-1 from
undergoing apoptosis. To test this hypothesis, ECs were
transfected with control (pcDNA3) or HO-1 expression
vectors and cocultured with b-galactosidase–transfected
ECs. When cocultured with control ECs (pcDNA3), TNF-a
plus Act.D induced apoptosis of b-galactosidase–transfected
ECs (that do not express HO-1). However, when cocul-
tured with ECs expressing HO-1, b-galactosidase–trans-
fected ECs were protected from TNF-a plus Act.D–medi-
ated apoptosis (Fig. 6).
Expression of Endogenous HO-1 Inhibits EC Apoptosis
via CO. We questioned whether upregulation of endog-
enous HO-1 by heme would suppress EC apoptosis. The
data illustrated in Fig. 7 suggest that this is the case. Expo-
pression vector per 3 3 105 cells (Fig. 2). All subsequent
experiments were carried out using these experimental
conditions.
The Antiapoptotic Function of HO-1 Requires Its Enzymatic
Activity. To test whether the antiapoptotic action of HO-1
was dependent on its enzymatic action, HO-1 activity was
blocked using SnPPIX. When HO-1 activity was blocked
by SnPPIX, HO-1 was no longer able to prevent EC apop-
tosis (Fig. 3), and the antiapoptotic effect of bcl-2 was not
impaired by SnPPIX (Fig. 3). CoPPIX, which has a similar
structure to SnPPIX but does not inhibit HO activity, did
not suppress the antiapoptotic effect of HO-1 or that of
bcl-2 (Fig. 3). These protoporphyrins had no detectable ef-
fect per se on EC viability (Fig. 3).
Endogenous CO Mediates the Antiapoptotic Effect of
HO-1. Since HO-1 enzymatic activity is needed for its
antiapoptotic effect, this suggests that this antiapoptotic ef-
fect is mediated through one or more end products of
heme catabolism by HO-1, i.e., bilirubin, iron, and/or
CO. We tested if CO would account for the antiapoptotic
effect of HO-1. ECs were transiently transfected with HO-1
and treated with Hb to scavenge CO. Under these condi-
tions, the antiapoptotic effect of HO-1 was suppressed (Fig.
Figure 6. ECs that express HO-1 suppress apoptosis of ECs that do not
express HO-1. 2F-2B ECs were transfected with control (pcDNA3; I and
II) or HO-1 (III) expression vectors. 16 h after transfection, ECs were
harvested, washed, and cocultured at a ratio of 1:1 with ECs transfected
with b-galactosidase (I and II) or with b-galactosidase plus HO-1 (III).
Cocultures were maintained for an additional 24 h before induction of
apoptosis by TNF-a plus Act.D. The percentage of survival was evalu-
ated by counting the number of b-galactosidase–positive cells that re-
tained normal morphology. Gray bars represent ECs treated with Act.D
and black bars represent ECs treated with TNF-a plus Act.D. Results
shown are the mean 6 SD from duplicates taken from one representative
experiment out of three.
Figure 7. Upregulation of endogenous HO-1 expres-
sion inhibits EC apoptosis via CO. (A) 2F-2B ECs were
cotransfected with a b-galactosidase expression vector and
exposed to FePP. Apoptosis was induced by TNF-a and
Act.D. Gray bars represent ECs treated with Act.D and black
bars represent ECs treated with TNF-a plus Act.D. The
results shown are the mean 6 SD from duplicate wells
taken from one representative experiment out of three. (B)
2F-2B ECs were cotransfected with a b-galactosidase ex-
pression vector and exposed to FePP (6.25 mM). Where
indicated, ECs were treated with Hb (50 mM). The results
shown are the mean 6 SD from duplicate wells taken from
one representative experiment out of three.1020 Carbon Monoxide Suppresses Endothelial Cell Apoptosis
sure to heme protected ECs from TNF-a plus Act.D–
mediated apoptosis (Fig. 7). This protective effect was ob-
served only at heme concentrations ranging from 5 to 7
mM and was lost at higher concentrations, suggesting that
heme becomes cytotoxic at concentrations higher than 10
mM (35; Fig. 7). The antiapoptotic effect of heme was de-
pendent on the generation of CO, since heme was no
longer able to suppress EC apoptosis when CO was scav-
enged by Hb (Fig. 7).
Iron Chelation Protects ECs from Apoptosis. The observa-
tion that CO can prevent EC apoptosis (Figs. 4 and 5) con-
trasts with the notion that the antiapoptotic effect of HO-1
relies exclusively on its ability to prevent intracellular iron
accumulation (34). Given that overexpression of HO-1 in
ECs resulted in significant upregulation of ferritin expres-
sion (data not shown), we questioned whether elimination
of reactive intracellular iron such as it occurs when ferritin
is expressed would contribute to prevent TNF-a–mediated
apoptosis of ECs. To mimic the iron chelator effect of fer-
ritin, we used the iron chelator DFO and tested whether
DFO would suppress EC apoptosis. The data illustrated in
Fig. 8 suggest that this is the case. Induction of EC apopto-
sis by TNF-a plus Act.D was suppressed by DFO (Fig. 8).
When HO-1 activity was inhibited by SnPPIX or the ac-
tion of CO was suppressed by Hb, DFO was still able to
prevent EC apoptosis (Fig. 8).
CO and Iron Chelation Have Additive Effects in Protecting
ECs from Apoptosis. Given the ability of both CO and
iron chelation to suppress EC apoptosis, we asked whether
these two biological functions, engendered by HO-1,
would act together to suppress EC apoptosis. Under inhibi-
tion of HO activity by SnPPIX, exposure to low levels of
CO (250 ppm) did not suppress EC apoptosis significantly.
When used alone, DFO (100 mM) suppressed EC apopto-
sis, but to a lesser extent than HO-1 (Fig. 9). However,
when ECs were exposed to both CO (250 ppm) and DFO
(100 mM), inhibition of EC apoptosis was comparable to
that achieved with the expression of HO-1.
Figure 8. Iron chelation by DFO suppresses EC apoptosis. (A) 2F-2B
ECs were transfected with a b-galactosidase expression vector and ex-
posed to DFO. Gray bars represent ECs treated with Act.D alone and
black bars represent ECs treated with TNF-a plus Act.D. (B) 2F-2B ECs
were cotransfected as described above in A. Where indicated (1), HO-1
enzymatic activity was inhibited by SnPPIX and iron was chelated by
DFO, as described above in A. Gray bars represent ECs treated with
Act.D and black bars represent ECs treated with TNF-a plus Act.D. (C)
2F-2B ECs were cotransfected as described above in A. Where indicated
(1), CO was removed from the culture medium by Hb and/or iron was
chelated by DFO as described above in A and B. Gray bars represent ECs
treated with Act.D and black bars represent ECs treated with TNF-a plus
Act.D. Results shown (A, B, and C) are the mean 6 SD from duplicate
wells taken from one representative experiment out of three.
Figure 9. Iron chelation and CO have additive effects in suppressing
EC apoptosis. 2F-2B ECs were cotransfected with b-galactosidase and
HO-1 (b-actin/HO-1) expression vectors. Where indicated (1), cells
were treated with the inhibitor of HO enzymatic activity SnPPIX. ECs
were exposed to CO (250 ppm) and to the iron chelator DFO. Gray bars
represent ECs treated with Act.D and black bars represent ECs treated
with TNF-a plus Act.D. The results shown are the mean 6 SD from du-
plicate wells taken from one representative experiment out of three.1021 Brouard et al.
The Antiapoptotic Effect of HO-1 Is Not Mediated by Gua-
nylcyclase Activation or cGMP Generation. Most biological
functions attributed to CO have been linked to its ability to
bind guanylcyclase and increase the generation of cGMP
(15, 36, 37). Since cGMP can regulate apoptosis (38, 39),
we tested whether or not the antiapoptotic effect of HO-1
acted via the activation of guanylcyclase and/or the genera-
tion of cGMP. The data illustrated in Fig. 10 suggest that
this is not the case. Expression of HO-1 in ECs did not re-
sult in a detectable increase of cGMP-related functions as
illustrated by the absence of VASP phosphorylation, a pro-
tein phosphorylated by cyclic nucleotide–dependent pro-
tein kinases (protein kinase G-a/b; Fig. 10). This finding is
in keeping with that reported by others (40). Inhibition of
guanylcyclase activity by ODQ did not suppress the antiap-
optotic effects of HO-1, and the cGMP analogue 8-Br-
cGMP failed to suppress EC apoptosis (Fig. 10). That 8-Br-
cGMP acted as a cGMP analogue was shown by its ability
to induce VASP phosphorylation (Fig. 10). That ODQ was
efficient in suppressing guanylcyclase activity in ECs was
shown by its ability to prevent constitutive VASP phos-
phorylation in 2F-2B ECs (data not shown).
HO-1 Increases TNF-a–mediated Activation of p38 MAPK
in ECs. Given that HO-1 and/or CO can modulate p38
MAPK activation in monocyte/macrophages (Mf [33]),
we tested whether HO-1 and/or CO would have similar
effects in ECs. Stimulation of ECs with TNF-a resulted in
transient activation of JNK and p38 MAPK (Fig. 11), a
finding consistent with those of others (41). ERKs (42 and
44 kD) were constitutively active in resting ECs, and no
significant upregulation was detectable after TNF-a stimu-
lation (Fig. 11). Recombinant adenovirus–mediated over-
expression of HO-1 potentiated the ability of TNF-a to
activate p38 MAPK (Fig. 12), but not to activate JNK
(data not shown). Overexpression of b-galactosidase had
no detectable effect on the activation of either p38 MAPK
or JNK by TNF-a. Exposure of ECs to exogenous CO
activated p38 MAPK even in the absence of TNF-a
(Fig. 12).
The Mechanism by Which CO Prevents EC Apoptosis Acts
via the Activation of p38 MAPK. Since p38 MAPK can
regulate apoptosis (42), we investigated whether the ability
of HO-1 to modulate p38 MAPK activation was linked to
its ability to prevent EC apoptosis. We found that this is
the case. The antiapoptotic action of HO-1 was suppressed
when p38 MAPK activation was blocked by the pyridinyl
imidazol SB203580 (10–20 mM), a specific inhibitor of p38
MAPK (32). This effect was dose dependent in that in-
creasing concentrations of SB203580 were increasingly ef-
ficient in suppressing the antiapoptotic action of HO-1
(Fig. 13). Inhibition of p38 MAPK activation per se did not
sensitize ECs to TNF-a–mediated apoptosis (data not
shown). As expected, activation of p38 MAPK by TNF-a
was significantly inhibited (85–95%) in ECs exposed to
SB203580 (5–20 mM), compared with control ECs stimu-
lated by TNF-a in the absence of SB203580 (Fig. 13).
Similarly to SB203580, overexpression of a dominant neg-
ative mutant of p38/CSBP1 (43) also suppressed TNF-a–
mediated p38 MAPK activation, as tested by a kinase assay
using the activating transcription factor (ATF)-2 as a sub-
strate (data not shown). Overexpression of this dominant
negative mutant suppressed the ability of HO-1 to prevent
EC apoptosis (Fig. 13). This inhibitory effect was dose de-
pendent in that increasing amounts of the p38/CSBP1
dominant negative mutant were more efficient in suppress-
ing the antiapoptotic action of HO-1 (Fig. 13).
Figure 10. The antiapoptotic effect of HO-1 does not act via a cGMP-dependent pathway. (A) 2F-2B ECs were cotransfected with b-galactosidase
and HO-1 (b-actin/HO-1) expression vectors. HO-1–transfected cells were exposed to increasing doses of the guanylcyclase inhibitor ODQ. Gray bars
represent ECs treated with Act.D alone and black bars represent ECs treated with TNF-a plus Act.D. The results shown are the mean 6 SD from dupli-
cate wells taken from one representative experiment out of three. (B) Activation of guanylcyclase was monitored in BAECs by analyzing the phosphory-
lation of VASP. P-VASP (50 kD) and VASP (46 kD) are the phosphorylated and nonphosphorylated forms of VASP, respectively. (C) 2F-2B ECs were
with b-galactosidase or with b-galactosidase plus HO-1 (b-actin/HO-1) expression vectors as described above in A. Where indicated, ECs were exposed
to the cGMP analogue 8-Br-cGMP, as described in Materials and Methods. Gray bars represent ECs treated with Act.D and black bars represent ECs
treated with TNF-a plus Act.D. The results shown are the mean 6 SD from duplicate wells taken from one representative experiment out of three. (D)
Phosphorylation of VASP was analyzed by Western blot as described above in B. N.T., nontreated.1022 Carbon Monoxide Suppresses Endothelial Cell Apoptosis
sustaining inflammation and promoting vascular thrombosis
(25, 45). The mechanism by which apoptotic ECs promote
vascular thrombosis is thought to involve the expression of
procoagulant phospholipids by apoptotic bodies (49) and
presumably the exposure of the procoagulant subendothe-
lial matrix that is associated with EC apoptosis. In addition,
apoptotic cells can activate the complement cascade di-
rectly through the binding of C1q to apoptotic bodies (50),
and promote platelet adhesion (49) that will sustain inflam-
mation and thrombosis as well.
The observation that HO-1 prevents apoptosis induced
by different proapoptotic stimuli (23, 24; Fig. 1) suggests
that HO-1 suppresses one or several signaling pathways
that are common to a broad spectrum of proapoptotic
stimuli. The antiapoptotic effect of HO-1 has recently been
associated with increased cellular iron efflux through the
upregulation of an iron pump that remains to be fully char-
acterized (34). According to this study (34), HO-1 inhibits
apoptosis by limiting the availability of prooxidant-free
iron to participate in the generation of reactive oxygen spe-
cies through the Fenton reaction, a well-established com-
ponent in the signaling cascades leading to apoptosis (51).
We hypothesized that HO-1 may have additional effects
that could contribute to suppress EC apoptosis, such as by
generating CO. Data from L.E. Otterbein, A.M.K. Choi,
and colleagues have suggested that this may be the case in
fibroblasts (52). However, data from other laboratories
have suggested that in 293 cells CO is not antiapoptotic
(34). Moreover, CO has been suggested to be proapoptotic
in ECs (53). This data suggests that HO-1 can suppress EC
apoptosis and that the antiapoptotic effect of HO-1 is me-
diated through the generation of CO (Figs. 4, 5, and 7).
The observation that the elimination of endogenous CO
by Hb abrogates the cytoprotective effect of HO-1 (Figs. 4
and 5) supports the notion that, in the absence of CO,
other biological functions engendered by HO-1, i.e., up-
regulation of ferritin expression and subsequent iron chela-
tion, are not sufficient per se to prevent EC apoptosis (Figs.
4 and 7). Given the above, it is difficult to understand why
iron chelation by DFO can protect ECs from apoptosis,
even under conditions in which the action of CO is pre-
vented (i.e., inhibition of HO-1 activity by SnPPIX or
elimination of CO by Hb; Fig. 8). At least two possible in-
terpretations may explain these observations: (a) DFO may
Figure 11. Activation of MAPK by TNF-a. (A) BAECs were stimu-
lated with TNF-a (10 ng/ml; time 0) and MAPK phosphorylation was
monitored by Western blot (0, 5, 15, 30, 60, and 120 min after TNF-a
stimulation) using antibodies directed against the phosphorylated forms of
each MAPK. One single membrane was used for all the stainings shown.
Experiments were repeated three times with virtually identical results.
n.s., nonspecific band. (B) Phosphorylation of different MAPKs was
quantified. The results were presented as fold induction in arbitrary units
(A.U.), compared with time 0, before TNF-a stimulation. The results in
B correspond to the membranes shown in A.
Discussion
EC apoptosis is a prominent feature associated with acute
and/or chronic inflammation such as it occurs during hy-
peroxia (44), endotoxic shock (25), arteriosclerosis (26), isch-
emia reperfusion injury (45, 46), and acute or chronic graft
rejection (23, 47, 48). Presumably, EC apoptosis contrib-
utes to the development of these inflammatory reactions by
Figure 12. HO-1 and CO modulate p38 MAPK activation in ECs. (A)
BAECs  were either nontransduced (NT), transduced with a b-galactosidase
(bgal.), or HO-1 recombinant adenovirus, and were left untreated (2) or treated
(1) with TNF-a (10 ng/ml for 15 min). p38 MAPK phosphorylation was mon-
itored by Western blot using antibodies directed against the phosphorylated
forms of each MAPK. Results are presented as fold induction of MAPK activa-
tion by TNF-a in arbitrary units (A.U.), compared with time 0, before TNF-a
stimulation. (B) BAECs were stimulated (1) or not (2) by TNF-a (10 ng/ml,
30 min) in the presence or absence of CO (10,000 ppm). Phosphorylation of p38
MAPK was quantified as in A. The results are presented as fold induction of
MAPK activation by TNF-a in arbitrary units (A.U.).1023 Brouard et al.
have a higher ability to “eliminate” free iron compared
with ferritin, and/or (b) DFO may have additional effects
that contribute to prevent EC apoptosis, independently of
its ability to eliminate free iron. In any case, these observa-
tions suggest that DFO does not, at least fully, mimic the
effect of HO-1–mediated ferritin expression in preventing
EC apoptosis.
Our data also suggest that CO, generated by cells that
express HO-1, acts as an intercellular signaling molecule to
prevent apoptosis of cells that do not express HO-1 (Fig.
6). If a similar effect of CO would occur in vivo, these data
would suggest that vascular ECs at sites of inflammation
might protect neighboring cells, such as infiltrating leuko-
cytes that immigrate into sites of inflammation or smooth
muscle cells in blood vessels from undergoing apoptosis.
The antiapoptotic effect of HO-1 in ECs is not mediated
by guanylylcyclase and/or by the generation of cGMP (Fig.
10). This is in contrast to data showing that inhibition of
guanylcyclase suppresses the antiapoptotic effect of HO-1
and/or CO in fibroblasts (51). Our interpretation is that
the mechanism by which HO-1 and/or CO prevents ap-
optosis is cell type specific.
Based on the finding by Otterbein et al. that HO-1/CO
activates p38 MAPK in Mf (33), we tested whether HO-1
and/or CO would have similar effects in ECs. We found
that this is the case (Fig. 12). However, contrary to Mf,
exogenous CO per se induced the activation of p38 MAPK
in ECs, whereas HO-1 did not (Fig. 12). Possible explana-
tions for the difference between HO-1 and CO in regulat-
ing p38 MAPK activation include the following. Whereas
CO generated by HO-1 activates p38 MAPK, other end
products of HO-1 activity may inhibit p38 activation. Al-
ternatively, the level of CO, generated by HO-1, is signifi-
cantly lower than exposure to exogenous CO as we used it.
Whatever the explanation, these data show that CO can
specifically modulate the activation of p38 MAPK.
We also found that the antiapoptotic effect of HO-1/CO
acts via the activation of a transduction pathway involving
the activation of p38 MAPK (Fig. 13). This is consistent
with findings by others showing that activation of p38
MAPK is key in regulating apoptosis in a variety of cell
types including the kidney epithelial cell line HeLa (54),
cardiac muscle cells (55), and lymphoid Jurkat T cells (54,
56). The mechanism by which the activation of p38
MAPK modulates the induction of apoptosis is not well
understood.
In conclusion, our findings suggest that CO, generated
through heme catabolism by HO-1, acts as an antiapoptotic
molecule that can suppress EC apoptosis. We show that the
mechanism of action of CO involves the activation of p38
MAPK. These findings further support the notion that
HO-1 acts as a protective gene and thereby contributes to
prevent a series of inflammatory reactions that are associ-
ated with EC apoptosis.
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Figure 13. The antiapoptotic
effect of HO-1 acts via the acti-
vation of p38 MAPK. (A) 2F-2B
ECs were cotransfected with
b-galactosidase, control (pc-
DNA3), or HO-1 (b-actin/
HO-1) expression vectors.
Where indicated, ECs were
treated with the p38 kinase in-
hibitor SB203580. Gray bars
represent ECs treated with
Act.D alone and black bars rep-
resent ECs treated with TNF-a
plus Act.D. The results shown
are the mean 6 SD from dupli-
cate wells taken from one repre-
sentative experiment out of
three. (B) BAECs were trans-
fected with a control (pcDNA3)
vector and stimulated with
TNF-a in the presence (d) or
absence (s) of the p38 kinase in-
hibitor SB203580 (20 mM).
MAPK phosphorylation was monitored by Western blot (0, 5, 15, 30, 60, and 120 min after TNF-a stimulation) using antibodies directed against the
phosphorylated forms of each MAPK. (C) 2F-2B ECs were cotransfected with b-galactosidase, control, HO-1 (b-actin/HO-1), and where indicated
with a phosphorylation-deficient p38/CSBP1 dominant negative mutant (DNM) expression vector. The values indicate the amount of vector used, in
nanograms of DNA per 300 3 103 cells. Apoptosis was induced as in A. Gray bars represent ECs treated with Act.D and black bars represent ECs treated
with TNF-a plus Act.D. The results shown are the mean 6 SD from duplicate wells taken from one representative experiment out of three. (D) The ex-
pression of the p38/CSBP1 dominant negative mutant was confirmed by Western blot using an anti-p38 specific antibody. No Tr., nontransfected ECs.1024 Carbon Monoxide Suppresses Endothelial Cell Apoptosis
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